Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 520,225 |
|
|||||
| News | - | ||||||
| Day High | 4.54 | Low High |
|||||
| Day Low | 4.25 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Pyxis Oncology Inc | PYXS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.15 | -3.37% | 4.30 | 16:19:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.40 | 4.25 | 4.54 | 4.30 | 4.45 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,512 | 520,225 | $ 4.39 | $ 2,281,207 | - | 1.35 - 6.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:27:05 | 2 | $ 4.33 | USD |
Pyxis Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 189.7M | 44.32M | - | 0 | -73.79M | -1.66 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Pyxis Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PYXS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.86 | 4.88 | 4.06 | 4.41 | 444,745 | -0.56 | -11.52% |
| 1 Month | 4.13 | 6.18 | 4.06 | 5.04 | 675,886 | 0.17 | 4.12% |
| 3 Months | 3.80 | 6.85 | 3.16 | 5.13 | 800,707 | 0.50 | 13.16% |
| 6 Months | 1.63 | 6.85 | 1.35 | 4.41 | 555,216 | 2.67 | 163.80% |
| 1 Year | 3.23 | 6.85 | 1.35 | 3.85 | 422,381 | 1.07 | 33.13% |
| 3 Years | 19.00 | 19.00 | 1.10 | 4.25 | 604,946 | -14.70 | -77.37% |
| 5 Years | 19.00 | 19.00 | 1.10 | 4.25 | 604,946 | -14.70 | -77.37% |
Pyxis Oncology Description
| Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. |
